Healthcare Industry News: MammaPrint
News Release - July 10, 2012
Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory BoardIRVINE, Calif. and AMSTERDAM, July 10, 2012 -- (Healthcare Sales & Marketing Network) -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Dr. Mark Gittleman, Medical Director of Breast Care Specialists and Advanced Breast Care Imaging, has joined the company's Medical Advisory Board. The board will play a key role in advising Agendia on the clinical application of its extensive product pipeline, including its Symphony suite of tests for breast cancer and its ColoPrint test for colon cancer.
As a breast cancer specialist, Dr. Gittleman has a vested interest in new technologies that enable medical professionals to better understand the biology of breast cancer, thereby helping patients attain better outcomes through the application of validated, clinically useful technologies such as Agendia's MammaPrint, BluePrint, TargetPrint and TheraPrint gene profiling tests. He is a past president of the American Society of Breast Surgeons. Dr. Gittleman currently serves on the ASBS Coding and Reimbursement and Breast Imaging Technology committees and is a reviewer for Ultrasound and Stereotactic certification applicants.
"With his vast knowledge and experience in breast imaging and minimally invasive biopsy techniques, Dr. Gittleman brings a unique perspective to our growing Medical Advisory Board," said David Macdonald, CEO of Agendia. "As Agendia invests significantly in clinical research studies to support the use of new diagnostic tests, our Medical Advisory Board will be an integral part of our clinical trial development. We look forward to working with Dr. Gittleman in our efforts to advance the future of healthcare and bring personalized medicine to breast and colon cancer patients."
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.
For more information, please visit www.agendia.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.